Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6TS1N)

• Drug Name: Phendimetrazine Drug Info
• Synonyms: Adphen; Antapentan; Dyrexan; Fendimetrazina; Hyrex; Mephenmetrazine; Phendimetrazinum; Sedafamen; Wehless; Adipost (TN); Adphen (base); Appecon (TN); Bontril PDM (TN); Fendimetrazina [INN-Spanish]; Melfiat (TN); Obezine (TN); Phendiet (TN); Phendimetrazine (INN); Phendimetrazine [INN:BAN]; Phendimetrazinum [INN-Latin]; Plegine (TN); Statobex (TN); X-Trozine; Anorex-SR (TN); Prelu-2 (TN); Phendimetrazine, (2S-trans)-isomer; D-2-Phenyl-3,4-dimethylmorpholine; Morpholine, 3,4-dimethyl-2-phenyl; (+)-3,4-Dimethyl-2-phenylmorpholine; (+)-Phendimetrazine; (2R-trans)-3,4-Dimethyl-2-phenylmorpholine; (2S,3S)-3,4-Dimethyl-2-phenylmorpholine; 3,4-Dimethyl-2-phenylmorpholine; 3,4-Dimethyl-2-phenyltetrahydro-1,4-oxazine; 3-Phenyl-2-methylmorpholine

Indication

Disease Entry	ICD 11	Status	REF
Obesity	5B81	Approved	[1]

• Therapeutic Class: Anorexigenic Agents
• Cross-matching ID:
  PubChem CID: 30487
  ChEBI ID: CHEBI:8059
  CAS Number: CAS 634-03-7
  TTD Drug ID: DM6TS1N
  ACDINA Drug ID: D00523

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor alpha-1B (ADRA1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methamphetamine	DMPM4SK	Anxiety		Approved	[3]
Propericiazine	DME9JNL	Psychiatric disorder	6E8Z	Approved	[4]
Methoxamine	DMF5XQH	Hypertension	BA00-BA04	Approved	[5]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[6]
TIOSPIRONE	DME5QDP	N. A.	N. A.	Discontinued in Phase 3	[7]
Sunepitron	DM6M8ZX	N. A.	N. A.	Discontinued in Phase 3	[8]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[9]
SOU-001	DMPAEK5	Urinary incontinence	MF50.2	Discontinued in Phase 2	[10]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[11]
WB-4101	DMQU8B1	N. A.	N. A.	Terminated	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-1B (ADRA1B)	TTBRKXS	ADA1B_HUMAN	Antagonist	[2]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
• [3] Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9.
• [4] Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91.
• [5] Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2.
• [6] A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
• [7] 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
• [8] An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
• [9] A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
• [10] Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
• [11] Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
• [12] Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.